In yesterday’s Wall Street session, Kiniksa Pharmaceuticals Ltd. (NASDAQ:KNSA) shares traded at $20.20, up 3.70% from the previous session.
5 analysts cover Kiniksa Pharmaceuticals Ltd. (NASDAQ:KNSA), according to research data. The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $32.00 and a low of $20.00, we find $23.00. Given the previous closing price of $19.48, this indicates a potential upside of 18.07 percent. KNSA stock price is now 37.14% away from the 50-day moving average and 46.37% away from the 200-day moving average. The market capitalization of the company currently stands at $1.38B.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
The stock has received a hold rating from 0 analysts and a buy rating from 5. Brokers who have rated the stock have averaged $24.60 as their price target over the next twelve months.
With the price target enhanced from $25 to $40, BofA Securities maintained Buy rating for Kiniksa Pharmaceuticals Ltd. (NASDAQ: KNSA).
In other news, Quart Barry D, Director sold 21,959 shares of the company’s stock on Nov 29. The stock was sold for $354,638 at an average price of $16.15. Upon completion of the transaction, the Director now directly owns 0 shares in the company, valued at $0.0. An SEC document containing details of the transaction can be found on the SEC’s website. On Nov 07, CHIEF MEDICAL OFFICER Paolini John F. sold 28,357 shares of the business’s stock. A total of $430,459 was realized by selling the stock at an average price of $15.18. This leaves the insider owning 36,335 shares of the company worth $0.73 million. Insiders disposed of 74,723 shares of company stock worth roughly $1.51 million over the past 1 year. A total of 0.30% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in KNSA stock. A new stake in Kiniksa Pharmaceuticals Ltd. shares was purchased by ENVESTNET ASSET MANAGEMENT INC during the first quarter worth $5,501,000. QUBE RESEARCH & TECHNOLOGIES LTD invested $2,559,000 in shares of KNSA during the first quarter. In the first quarter, ESSEX INVESTMENT MANAGEMENT CO LLC acquired a new stake in Kiniksa Pharmaceuticals Ltd. valued at approximately $2,407,000. MASSACHUSETTS FINANCIAL SERVICES CO /MA/ acquired a new stake in KNSA for approximately $1,675,000. TEJARA CAPITAL LTD purchased a new stake in KNSA valued at around $980,000 in the second quarter. In total, there are 207 active investors with 45.50% ownership of the company’s stock.
On Wednesday morning Kiniksa Pharmaceuticals Ltd. (NASDAQ: KNSA) stock kicked off with the opening price of $19.48. During the past 12 months, Kiniksa Pharmaceuticals Ltd. has had a low of $9.63 and a high of $20.00. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 6.30, and a quick ratio of 5.70. The fifty day moving average price for KNSA is $14.86 and a two-hundred day moving average price translates $13.83 for the stock.
The latest earnings results from Kiniksa Pharmaceuticals Ltd. (NASDAQ: KNSA) was released for Jun, 2023. According to the Biotechnology Company, earnings per share came in at $0.21, beating analysts’ expectations of -$0.17 by 0.38. This compares to -$0.36 EPS in the same period last year. The net profit margin was 83.10% and return on equity was 59.30% for KNSA. The company reported revenue of $48.34 million for the quarter, compared to $32.19 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 50.19 percent. For the current quarter, analysts expect KNSA to generate $62.2M in revenue.
Kiniksa Pharmaceuticals Ltd.(KNSA) Company Profile
Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that completed Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. Kiniksa Pharmaceuticals, Ltd. was incorporated in 2015 and is based in Hamilton, Bermuda.
